Various cancer therapeutic agents have been demonstrated to augment TRAIL-induced apoptosis through induction of DR5 expression [24-30], indicating that DR5 expression levels might be involved in resistance to TRAIL. The gene discussed is TNFSF10; the disease is cancer.